期刊文献+

卡维地洛对慢性心力衰竭合并肾功能不全患者的疗效观察 被引量:2

Carvedilol in treatment of patients with chronic heart failure complicated by chronic renal dysfunction
下载PDF
导出
摘要 目的观察卡维地洛对慢性心力衰竭合并肾功能不全患者的临床疗效。方法将60例慢性心力衰竭合并肾功能不全的患者采用数字表分组法随机分为两组,治疗组在接受常规心力衰竭治疗的基础上加用卡维地洛直到目标剂量,对照组不用卡维地洛,其余治疗措施相同。比较治疗12周后两组患者心功能和肾功能的变化。结果治疗组患者治疗12周后左室舒张末期内径、左室收缩末期内径较治疗前明显缩小(均P〈0.05),左室射血分数较治疗前明显增高(P〈0.05),且均优于对照组(均P〈0.05)。治疗12周后血尿素氮、肌酐、β2-微球蛋白较对照组明显降低(均P〈0.05)。结论卡维地洛能明显改善慢性心力衰竭合并肾功能不全患者的心功能和肾功能。 Objective To evaluate the clinical efficacy of carvedilol in treatment of patients with chronic heart failure (CHF) complicated by chronic renal dysfunction (CRF). Methods Sixty CHF patients complicated with CRF were divided into two groups: control group (receiving regular treatment) and treatment group (receiving oral carvedilol in a ramped dose scheme based on regular treatment). Clinical parameters including cardiac function and renal function of two groups were assessed before and after treatment, Results After 12 weeks of carvidilol therapy, the left ventricular end-diastolic dimension (LVEDD) and left ventricular end-systolic dimension (LVESD) were decreased significantly in treatment group (both P〈0.05), while left ventricular ejection fraction (LVEF) improved (P〈0.05); the blood urea nitrogen (BUN), serum creatinine (Cr) and blood J52 -microglobulin (β2-MG) were decreased significantly (all P〈0.05). All of these results in treatment group were better than those in control group (all P〈0.05). Conclusion Carvedilol may improve both cardiac function and renal function in CHF patients with CRF.
出处 《浙江医学》 CAS 2010年第4期485-487,共3页 Zhejiang Medical Journal
关键词 卡维地洛 慢性心力衰竭 肾功能 疗效 Carvedilol Chronic Heart Failure Renal Function Efficacy
  • 相关文献

参考文献7

  • 1Arnold J M O,Yusuf S,Young J,et al.Prevention of heart failure in patients without known left ventricular dysfunction:The Heart Outcomes Prevention Study (HOPE)[J].Circulation,2003,107:1284. 被引量:1
  • 2Packer M,Fowler M B,Roecker E B,et al.for the carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group:Effect of carvedilol on the morbidity of patients with severe chronic heart failure:Results of the carvedilol Prospective Randomized Cumulative Survival (COPERNICUS)Study[J].Cir-culation,2002,106:2194. 被引量:1
  • 3Poole-Wilson P A,Swedberg K,Cleland J G,et al.Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET):randomised controlled trial[J].Lancet,2003,362 (2):7-13. 被引量:1
  • 4Metra M,Nodari S,Giubbini R,et al.Differential effects beta-blockers in patients with heart failure.A prospective,randomized,double-blind comparison of the long-term effects of metoprolol versus carvedilol[J].Circulation,2000,102:546. 被引量:1
  • 5Frantz R P,Olson L J,Grill D,et al.Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure[J].Am Heart J,2005,149(3):541-547. 被引量:1
  • 6Hart P D,Bakris G L.Should beta-blockers be used to control hypertension in people with chronic kidney disease[J]? Semin Nephrol,2007,27 (2):555-564. 被引量:1
  • 7Horani M H,Haas M J,Mooradian A D.Suppression of hyperglycemia-induced superoxide formation and endothelin-1 gene expression by carvedilol[J].Am J Ther,2006,13(1):2-7. 被引量:1

同被引文献27

  • 1唐炯,燕纯伯.慢性心力衰竭治疗现状[J].心血管病学进展,2005,26(6):569-572. 被引量:6
  • 2任鹤民,张金芬.螺内酯治疗充血性心力衰竭疗效观察[J].中国误诊学杂志,2007,7(3):482-483. 被引量:4
  • 3Bristow MR. β -adrenergic receptor blockade in chronic heart failure [J].Circulation,2000,101 (5):558-569. 被引量:1
  • 4Hunt SA,Abraham WT, Chin MH,et al.ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult[J].Circulation,2005,112(12):e 154-e235. 被引量:1
  • 5ESC guidelines for chronic heart failure:2005 update[J].Eur Heart J,2005,260:1115-1140. 被引量:1
  • 6Garg R,Yusuf S.Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure.Collaborative Group on ACE Inhibitor Trials[J].JAMA,1995,273(18):1450-1456. 被引量:1
  • 7Flather MD,Yusuf S,Kφber L,et al.Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:a systematic overview of data from individual patients. ACE- Inhibitor Myocardial Infarction Collaborative Group[J].Lancet,2000,355(9215):1575-1581. 被引量:1
  • 8de Groote P, Isnard R,Assyag P, et al.Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey [J].Eur J Heart Fail,2007,9(12): 1205-1211. 被引量:1
  • 9Faris R,Flather M,Purcell H,et al.Current evidence supposing the role of diuretics in heart failure:a meta analysis of randomized controlled trials[J].Int J Cardiol,2002,82(2): 149-158. 被引量:1
  • 10Krum H,Cameron RDiuretics in the treatment of heart failure:mainstay of therapy or potential hazard? [J].J Card Fail,2006,12(5):333-335. 被引量:1

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部